While reporting strong fourth quarter 2020 financials, AbbVie Inc. stressed during its 3 February earnings call that its JAK1 inhibitor Rinvoq likely will not present the same safety issues that a post-approval study showed for Pfizer Inc.’s JAK inhibitor Xeljanz. Company president Michael Severino said safety data compiled from Rinvoq’s use in rheumatoid arthritis to date shows no more than the expected level of major adverse cardiovascular events or malignancies.
On 27 January, Pfizer reported that a Phase IV study of Xeljanz (tofacitinib) required by the US Food and Drug...








